CYBERLOQ TECHNOLOGIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CYBERLOQ TECHNOLOGIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $197 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $19.9K | Mar 31, 2022 |
| FY2018 | Dec 31, 2018 | $10.4K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $3.9K | Mar 29, 2018 |
| FY2015 | Dec 31, 2015 | $6.2K | Oct 17, 2016 |
| FY2015 | Dec 31, 2014 | $11.6K | Oct 17, 2016 |
| FY2014 | Dec 31, 2013 | $42.1K | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | $24.2K | Jan 13, 2015 |
| FY2012 | Dec 31, 2011 | $6.4K | Apr 9, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $15.0K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $16.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.7K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $197 | Mar 29, 2023 |
| FY2020 | Dec 31, 2020 | $19.9K | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $77.2K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $10.4K | Apr 7, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $6.2K | Oct 17, 2016 |
| FY2015 | Dec 31, 2014 | $11.6K | Oct 17, 2016 |
| FY2014 | Dec 31, 2013 | $45.5K | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | $24.2K | Jan 13, 2015 |
| FY2012 | Dec 31, 2011 | $6.4K | Apr 9, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.13M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($989.5K) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($1.03M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($979.0K) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.09M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($983.3K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($521.4K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.04M) | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | ($559.9K) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($520.9K) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($771.6K) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($752.9K) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($367.3K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($682.3K) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.06M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($860.7K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($521.3K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.03M) | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | ($650.7K) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($458.3K) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $180.1K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $2.1K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.2K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $30.6K | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $76.7K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $147.2K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $192.6K | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $67.4K | Oct 17, 2016 |
| FY2014 | Dec 31, 2013 | $82.7K | Apr 15, 2015 |
| FY2014 | Dec 31, 2012 | $28.5K | Apr 15, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.0K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $51.9K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $18.9K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $24.8K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $10.9K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $7.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $18.6K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.0K | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $3.5K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $2.5K | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($775.1K) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($715.1K) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($340.8K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($372.0K) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($664.6K) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($306.2K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($339.6K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($413.8K) | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | ($564.1K) | Mar 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.53M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.84M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.46M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $341.1K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $264.5K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $27.4K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $485.3K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $580.7K | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $799.5K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $31.8K | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.19M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.83M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.02M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $324.1K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $299.5K | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $337.5K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $144.9K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $94.4K | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $205.1K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $315.7K | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.67M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($988.5K) | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $437.2K | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | $17.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | ($35.0K) | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | ($310.0K) | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $340.4K | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $486.3K | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $594.4K | Apr 7, 2020 |
| FY2018 | Dec 31, 2016 | ($284.0K) | Mar 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.76M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($8.63M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($8.26M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($7.23M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($6.25M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($5.17M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.18M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($3.66M) | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | ($2.62M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($2.06M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $54.3K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $26.7K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $636 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $21.0K | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | $112.8K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $31.8K | Mar 29, 2018 |
| FY2017 | Dec 31, 2015 | $44.1K | Mar 29, 2018 |
| FY2016 | Dec 31, 2014 | $14.8K | Mar 29, 2017 |
| FY2015 | Dec 31, 2013 | $2.0K | Oct 17, 2016 |
| FY2014 | Dec 31, 2012 | $59 | Apr 15, 2015 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $32.5K | Mar 29, 2023 |
| FY2021 | Dec 31, 2021 | $34.6K | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $35.6K | Mar 31, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 29, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 138.51M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 128.79M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 122.59M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 119.09M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 82.75M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 74.04M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 68.13M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 65.83M | Apr 7, 2020 |
| FY2018 | Dec 31, 2017 | 61.98M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 44.46M | Mar 29, 2018 |